Apollomics Inc., a biopharmaceutical company, has addressed a comment from the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3, initially filed on April 1, 2024. The SEC's comment, dated April 15, 2024, questioned the residency of the company's board of directors, specifically the discrepancy between the company's previous response and the disclosure that two directors are based in mainland China. Apollomics clarified that all board members reside outside of China and has amended the disclosure on page 22 of the Registration Statement accordingly. The amendment, known as Amendment No. 1, was filed via EDGAR. The company's legal representative, White & Case LLP, has invited the SEC to discuss any further questions or comments.

Apollomics Inc., a biopharmaceutical company, has addressed a comment from the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3, initially filed on April 1, 2024. The SEC's comment, dated April 15, 2024, questioned the residency of the company's board of directors, specifically the discrepancy between the company's previous response and the disclosure that two directors are based in mainland China. Apollomics clarified that all board members reside outside of China and has amended the disclosure on page 22 of the Registration Statement accordingly. The amendment, known as Amendment No. 1, was filed via EDGAR. The company's legal representative, White & Case LLP, has invited the SEC to discuss any further questions or comments.